Tuesday, 31 March 2020

New York Governor Confirms Cannabis Legalization By Budget “Not Likely”

Governor Andrew Cuomo said, during a Tuesday press conference about COVID-19, there was "too much, too little time" for adult use cannabis legalization.




New Study Finds Medical Marijuana Is Too Strong For Pain Relief

:Brendan Bures

Results of the study found that between 70-90% of legal marijuana products contained THC levels higher than 15%.

According to a new study published in the journal PLOS ONE, 90% of cannabis products sold in medical dispensaries contain levels of THC two to three times higher than what doctors recommend.
“We know that high-potency products should not have a place in the medical realm because of the high risk of developing cannabis-use disorders, which are related to exposure to high THC-content products,” Alfonso Edgar Romero-Sandoval, the study’s lead author, said.
For the study, researchers gathered more than 8,500 cannabis products across 653 dispensaries in legal medical marijuana states, including California, Colorado, Massachusetts, New Mexico, Maine, Vermont, Washington, New Hampshire, and Rhode Island. The goal was to analyze THC and CBD levels in medical marijuana products compared to recreational ones.
They also tested whether CBD and THC levels met those advertised, and if those levels were suitable to satisfying medical needs.
Results of the study found that between 70-90% of legal marijuana products contained THC levels higher than 15%. The researchers also noted a prior study focused on Washington state, where more than 90% of cannabis product contained more than 15% THC. This could mean the commercial market bears significant influence on medical products, the study’s authors wrote.
Pain Patients More LIkely To Develop Marijuana Dependence
Photo by rawpixel.com
“Several earlier studies showed that levels of up to 5% tetrahydrocannabinol (THC)—the main psychoactive compound in marijuana that provides pain relief as well as intoxication—were sufficient to reduce chronic pain with minimal side effects,” Romero-Sandoval said.
Researchers didn’t pinpoint any significant differences across state markets. However, they found medical dispensaries with products advertising low levels of CBD, around 2%. In recreational markets, CBD levels were closer to 1.3%. This was concerting because CBD can lower some of THC’s negative psychological effects, researchers say. As a medicine, the plant works best when utilizing the entourage effect, or when multiple cannabinoids work in conjunction with one another instead of one cannabinoid exclusively prioritized.
According to Romero-Sandoval, 60-80% of medical marijuana use is for pain relief. Introducing higher levels of THC immediately could not only create a dependence, but also cause patients to seek increased THC levels after developing a tolerance.
“Better regulation of the potency of medical marijuana products is critical,” Romero-Sandoval said. “The FDA regulates the level of over-the-counter pain medications such as ibuprofen that have dose-specific side effects, so why don’t we have policies and regulations for cannabis, something that is far more dangerous?”

Saturday, 28 March 2020

Scientists Sue DEA Over Alleged ‘Secret’ Document That Delayed Marijuana Research Expansion

The Drug Enforcement Administration (DEA) is finding itself in court over marijuana again after scientists filed a lawsuit against the agency, requesting “secret” documents that they allege DEA used to delay action on expanding cannabis research.
The Scottsdale Research Institute (SRI) is behind the suit. It’s one of more than 30 organizations that have submitted applications to DEA to become licensed cannabis manufacturers for research purposes.
Some background should be noted: In 2016, DEA announced it would expand marijuana research by approving additional growers beyond the sole source that has existed for half a century at the University of Mississippi. But after more than three years, applicants heard silence, and SRI filed an initial lawsuit alleging that the agency was deliberately holding up the process. A court mandated that it take steps to make good on its promise, and that case was dropped after DEA provided a status update.
This month, DEA finally unveiled a revised rule change proposal that it said was necessary due to the high volume of applicants and to address potential complications related to international treaties to which the U.S. is a party. A public comment period is now open, after which point the agency says it will finally approve an unspecified number of additional growers.

But what really accounted for the delay?

According to the plaintiffs in this new suit, after DEA said it would accept more cultivators, the Justice Department’s Office of Legal Counsel (OLC) secretly issued an opinion that interprets international treaty obligations as making it impossible to carry out the 2016 proposed rule while maintaining compliance.
The new revised rule aims to address the problem, in part by shifting jurisdiction over the cannabis to a single agency, DEA, which would purchase and technically own all of the cannabis grown by approved cultivators, and would then later sell the product directly to researchers.
That OLC document, which is not public, is the basis of SRI’s Freedom of Information Act (FOIA) complaint. The case was filed with the U.S. District Court for the District of Arizona on Wednesday and requests that the Justice Department be found guilty of unlawfully failing to make records available related to its interpretation of the Single Convention treaty, including the OLC opinion. It further states that DEA should release those documents and pay the plaintiff’s attorney fees.
Matt Zorn, an attorney working the case, told Marijuana Moment in a phone interview that it’s not clear what’s contained in the OLC opinion and that the uncertainty is “entirely the point” of the suit.
“I think we all know vaguely what it says—the subject matter of it—but we don’t know what it actually says,” he said. “That’s important because you need to know what that instruction was or what their interpretation of the law is to assess whether what they’re doing now is appropriate.”
The suit claims that SRI, “as a non-commercial company dedicated to advancing the state of medical care through clinical research, is directly harmed by this unlawful secrecy.”
“Because Defendants have failed to fully disclose their re-interpretation of federal law and treaty obligations as the law requires, Plaintiff lacks information necessary to protect its legal rights, including the right to have its application to manufacture marijuana for research processed in compliance with the Administrative Procedure Act and the [Controlled Substances Act],” the filing states.
SRI’s research objective for cannabis is to determine potential therapeutic benefits for veterans suffering from conditions such as post-traumatic stress disorder. “While DEA’s unlawful and dilatory conduct harms the public generally, the secrecy and delay have been especially harmful to our nations’ veterans,” the suit says.
“We deserve not only to know the scientific truth about medical marijuana use, but candor from our government, which includes disclosure of the ‘secret law’ the agency continues to rely on as a basis to delay and ultimately revamp the process for researching and manufacturing marijuana in this country,” the filing says. “Plaintiff brings this FOIA action so can understand the legal basis—if there is one—for the government’s conduct surrounding the Growers Program.”
While SRI acknowledged that DEA last week announced its revised rule change proposal, the suit states that the explanation about how it arrived at its determination “leaves Plaintiff and the public in the dark with respect to several critical considerations.” For example, it alleges, the notice doesn’t account for how the Justice Department advised the agency on the matter and which parts of the amended proposal would make the action compliant with international treaties.
“The answer to these questions and others presumably lies in the undisclosed OLC Opinion and related records that animated DOJ’s decision to sideline the Growers Program and prompted DEA to embark on this notice-and-comment rulemaking in the first place… In sum, using a secret OLC Opinion interpreting the CSA and a 1961 international treaty, DEA delayed processing applications to cultivate marijuana for research and now proposes to radically revamp federal law through rulemaking—rules which will loom large over the future of medical marijuana research, manufacture, and distribution going forward.”
The plaintiffs argue that DEA violated federal statute that prohibits the creation of a “secret law.” The statute says that federal agencies must make records—including final opinions and policy interpretations not published in the Federal Register—public.
“To block the Growers Program, DOJ formulated—through the OLC Opinion and related records—and DEA adopted to an undisclosed interpretation of the Single Convention and federal law contrary to the view espoused and published by DEA in the August 2016 Policy Statement, and contrary to the view of the State Department,” it continues, apparently referencing a letter the State Department sent to a senator in response to questions about the role of international treaties as it concerns expanding cannabis cultivation facilities.
In that letter, the department said nothing about the Single Convention prevents member nations from increasing the number of such facilities. “If a party to the Single Convention issued multiple licenses for the cultivation of cannabis for medical and scientific purposes, that fact alone would not be a sufficient basis to conclude that the party was acting in contravention of the Convention,” it read.
Read the State Department’s responses on international treaties and marijuana below:
State Dept Response on Single Convention by Marijuana Moment on Scribd
If the new lawsuit’s allegations prove accurate, it could help explain the role of former Attorney General Jeff Sessions, the anti-marijuana official who was reportedly involved in blocking research expansion.
The suit, which was first reported by Politico, goes on to say:
“For more than three years, Defendants relied on this undisclosed interpretation, contained in the OLC Opinion and related records, to make an end-run around the Administrative Procedure Act by unlawfully withholding and unreasonably delaying agency action on marijuana cultivation applications. The OLC Opinion has guided DEA’s actions—and its inaction… The government’s unlawful conduct under FOIA prevents Plaintiff and those similarly situated from timely and effectively vindicating legal rights under the Administrative Procedure Act, effectively rendering its protections and judicial review provisions meaningless.”
To resolve the issue, SRI said it wants DEA to be held accountable for violating federal law, release the documents and compensate them for the legal action. While this is a FOIA-related suit, the institute didn’t first seek the documents through a standard document request but instead filed the case under the law’s “Reading Room provision” that allows courts to force federal agencies to put records online, according to a Ninth Circuit ruling last year.
Sue Sisley, a researcher with SRI, told Marijuana Moment that the institute has generally had a good relationship with DEA over the years and doesn’t expect that it would unduly deny their application in retaliation for the institute’s repeated legal actions against the agency.
“I couldn’t fathom that that would happen, but I hope that the merits of our application are so clear that it would carry us forward,” she said. However, these licensing agreements are “not always a merit-based process so it is possible that if politics get deeply involved here that there could be a situation where licenses are awarded to friends of the government. We’re still praying that there is some merit-based system.”
Researchers and lawmakers have made clear that the current availability of federally authorized cannabis for research raises questions about the accuracy of tests that rely on it, as the quality is insufficient. As of now, there’s only one facility at the University of Mississippi that’s authorized to grow cannabis for researchers. The products developed at the university have been widely criticized by scientists and lawmakers. A study indicated that the facility’s cannabis is chemically more similar to hemp than marijuana available in state-legal markets.
“If adopted, these proposed rules would radically overhaul how medical marijuana manufacture and research will proceed in this country,” the plaintiffs wrote. “Better supply is needed for better research, and better research is needed not only because millions use medical marijuana every day, but also to facilitate informed policymaking at the federal and state levels, including legislation and drug scheduling decisions.”

Friday, 20 March 2020

Cannabis and coronavirus: Here’s what you need to know

Leafly Staff

coronavirus, COVID-19, infection, virus, cannabis and the flu
Masks are for patients and healthcare workers. If you're not sick, wash your hands. And don't pass that joint around. (Belkin & Co/AdobeStock)
The global concern over the novel coronavirus known as COVID-19 has many people taking precautions against contracting the virus. Here’s what we know about cannabis and COVID-19.

How cannabis users can stay healthy around coronavirus

Stop sharing joints, blunts, and bongs while coronavirus is spreading

The puff-and-pass customs surrounding cannabis are among the greatest pleasures of the plant. But passing around a joint is is a good way to spread any virus, including COVID-19. For now, stick to your own supply and offer a friendly elbow bump.

Wash your hands frequently

We can’t emphasize this enough. Thorough handwashing really, really, really does help prevent transmission of coronavirus, as well as other ailments. Before you sit down for a session or dig into some munchies, make sure to wash your hands for a count of 20 seconds. That’s as long as it takes to sing “Happy Birthday to You”—or the first chorus of Sublime’s “Smoke Two Joints.” Just saying.

Don’t buy into unproven coronavirus remedies

Given the general hype around CBD, expect to hear outlandish claims about its effect on coronavirus, most likely spread via social media. These claims are not true. There is no solid research on CBD and coronavirus.

Practice social distancing. Now.

Everyone in North America should now be fully into a social distancing regimen. That means:
  • If you can, work from home.
  • Reduce, limit, or eliminate trips to public gathering spots. Stop jamming the bars and cafes!
  • Keep 6 feet of distance between yourself and others.
  • Plan necessary shopping (groceries, medicine) for low-traffic hours, early morning or late night.
  • Postpone or cancel events. Weddings, birthday parties, card nights: No. Done.
  • Help people in high-risk categories. A simple trip to the grocery store could be a life-or-death decision for them. If you’re in a low-risk demographic, offer to pick up their items the next time you make a run.

Be cautious with cannabis around any virus

Smoking weed when you’re down with a virus: Not such a great idea. Leafly’s article Cannabis for colds and flu? Here’s what the experts say has a lot of helpful advice about integrating cannabis (or not) into the treatment and recovery from a normal flu. Yes, THC and CBD have pain-relieving, sleep-inducing, and anti-inflammatory properties.
But inhaling hot smoke is the last thing your lungs need when fighting a cold or flu. Do your research before medicating.
Stop shaking hands. A wave or friendly verbal greeting helps everyone. You don’t need to lock yourself in a panic room, but do consider your interactions with other people and with public surfaces when out and about.

Why are we doing this? Isn’t everyone eventually going to get it?

The point isn’t to seal up the virus in a jar, or halt it at our borders. That moment has passed. What we’re all working to do now is make sure the infections don’t all hit at once and overwhelm our limited medical supplies and hospital capacity.
If 100 people require a hospital’s Intensive Care Unit, and the ICU can only handle 15 at a time, 85 people may die needlessly. If the infections in those 100 people are spread out over many weeks and months, though, we can get most of them through this alive.

The Washington Post has one of the best visual explanations of why we’re all working to flatten the curve: 

How are we doing so far?

Not so great. Check out the United States’ trajectory on the latest graph:

Leave the face masks for ill patients and healthcare providers

The CDC and other health agencies are clear on this: Masks are meant to prevent already infected patients from spreading the virus, and to protect healthcare professionals working in high-risk environments. Frequent handwashing is far more effective than wearing a mask.

Be aware of COVID-19 symptoms

Don’t jam up the emergency room if it’s just a common cold, but get yourself tested if you fit the criteria for COVID-19 symptoms. Those include:
  • Fever
  • Cough
  • Shortness of breath
  • Have been in contact with a COVID-19 patient, or traveled recently to an area with ongoing spread.
Note: The definition of “area with ongoing spread” changes practically by the hour, and this item on the symptom list is becoming less important as the virus is recognized as extant in local communities.

Check yourself with this flow chart

Illustrator Wendy MacNaughton teamed up with UCSD infectious disease expert Eliah Aranoff-Spencer to create this updated guide, published on Medium.

Have a self-quarantine plan

At this point we’re talking about a spectrum, from choosing a work-at-home option (if you’re fortunate enough to have that choice) to a full-on home quarantine. The CDC has a page of recommendations for those who stay home with a suspected case of COVID-19.

Are bong condoms really a thing?

Absolutely! Get yourself one of these fun devices. One of our in-house experts suggests this $9.99 silicone MouthPeace from Mooselabs, which uses activated carbon filters. Jay the Cannabis Explorer reviews it in the video below:
Another suggestion: Pax Era mouthpiece covers can be had for $4.30 a pop from Delta 3D Studios. Use an X-Acto knife to cut a hole in the closed end and you’ve got yourself a personal lip caddy.
Note: Most viral transmission happens via the hands, so while you’re being so clever with your lips you should watch your fingers, which are holding a bong or vape that many others have just recently held as well. Just saying.

Will this affect cannabis product supplies?

Because all legal cannabis products are produced within the state in which they’re sold, industry experts aren’t expecting a shortage of actual cannabis due to import slowdowns.
That’s not to say there won’t be shortages or supply interruptions in certain products. Most vape batteries and wholesale vape cartridges are manufactured in China. Those supply chains have already seen slowdowns and interruptions due to quarantines impacting the Chinese manufacturing sector.
The US imports about 30 million Chinese vape pens and cartridges every month. Most shipments stopped due to the annual Chinese New Year shutdown in mid-January and haven’t fully resumed due to the coronavirus.
“A supply pinch is coming in weeks and will persist for months,” says Dan Fung, CEO of American Made Vapes. “Prices will rise. Shortages of packaging and vape pens could occur.”
Much of the packaging materials utilized by cannabis companies is also manufactured in China, so a slowdown in those materials may result in a slowdown in stateside production.
The development of new cannabis-related products may be slowed as well, as designers and manufacturers can’t rely on a steady supply of wholesale products and materials from China right now.

Will this affect 4/20 events?

The answer is yes. Organizers of 4/20 celebrations, which are now less than six weeks away, are already considering how a wider outbreak of COVID-19 could impact their events. Some have begun postponements or cancellations.
One cannabis store manager told Leafly he was putting a food truck ordered for 4/20 on hold because of health concerns. 4/20 festivals were already changing and evolving due to the expansion of legalization. The coronavirus outbreak may further accelerate that change in ways that are hard to predict right now.

What about legalization campaigns?

If COVID-19 spreads to more American cities, we may see more cancellations of larger events, gatherings, and festivals. Larger-scale shopping malls and commercial districts may see a downturn in pedestrian traffic. That may affect the ability of signature gatherers to bank enough names to qualify legalization initiatives by a given deadline.
Leafly’s Election 2020 page has a full rundown of all the state legalization campaigns currently aiming at the November 2020 ballot.